These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21810681

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R, Kaufman JL, Khoury HJ, King N, Shenoy PJ, Lewis C, Bumpers K, Hutchison-Rzepka A, Tighiouart M, Heffner LT, Lechowicz MJ, Lonial S, Flowers CR.
    Cancer; 2012 Jul 15; 118(14):3538-48. PubMed ID: 22535574
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
    Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N.
    Cancer; 2009 Oct 01; 115(19):4540-6. PubMed ID: 19593797
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.
    J Clin Oncol; 2009 Oct 20; 27(30):5023-30. PubMed ID: 19770386
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
    Braga P, Carvalho S, Gomes M, Guerra L, Lúcio P, Marques H, Negreiro F, Pereira C, Silva C, Teixeira A.
    Acta Med Port; 2010 Oct 20; 23(6):1025-34. PubMed ID: 21627880
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL, LYM-3001 study investigators.
    Lancet Oncol; 2011 Aug 20; 12(8):773-84. PubMed ID: 21724462
    [Abstract] [Full Text] [Related]

  • 11. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M.
    J Clin Oncol; 2013 Apr 20; 31(12):1506-13. PubMed ID: 23530110
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP.
    J Clin Oncol; 2010 Jun 20; 28(18):3035-41. PubMed ID: 20458031
    [Abstract] [Full Text] [Related]

  • 14. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
    Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, Walley T, Dickson R.
    Health Technol Assess; 2009 Jun 20; 13 Suppl 1():23-8. PubMed ID: 19567210
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA.
    Am J Hematol; 2002 Jul 20; 70(3):181-5. PubMed ID: 12111762
    [Abstract] [Full Text] [Related]

  • 16. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F, López-Guillermo A, Arenillas L, Montoto S, Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E.
    Eur J Haematol; 2006 Jan 20; 76(1):58-63. PubMed ID: 16343272
    [Abstract] [Full Text] [Related]

  • 17. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M, Italian Lymphoma Study Group.
    Cancer; 2007 Jul 01; 110(1):121-8. PubMed ID: 17503433
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2007 Apr 20; 25(12):1570-5. PubMed ID: 17353550
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D.
    J Clin Oncol; 2006 Sep 01; 24(25):4123-8. PubMed ID: 16896005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.